查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1781927

非小细胞肺癌治疗市场，按疗法、按配销通路、按癌症类型、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Non-Small Cell Lung Cancer Therapeutics Market, By Therapy, By Distribution Channel, By Cancer Type, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年非小细胞肺癌治疗市场规模价值 214.612 亿美元，2025 年至 2032 年的复合年增长率为 12.99%。

非小细胞肺癌治疗市场-市场动态

非小细胞肺癌治疗市场的发展受到持续吸烟和日益严重的环境污染导致全球肺癌发病率上升的推动，这推动了对高效治疗的需求。世界卫生组织称，肺癌是全球主要癌症杀手之一。此外，非小细胞肺癌分子机制的快速发展为标靶治疗和免疫疗法的研发开闢了道路，这些疗法有望实现更精准、毒性更低的治疗。对新的生物标记和治疗标靶的进一步研究有望创造更个人化的医疗模式。免疫疗法与标靶药物的结合取得了令人鼓舞的成果，能够改善患者的预后，尤其是在晚期患者中。

此外，液体活检等先进诊断技术的应用日益广泛，有助于识别和追踪早期治疗的反应，从而实现更早、更有效的治疗。新兴市场医疗基础设施的完善以及高端癌症治疗的普及也带来了巨大的成长机会。然而，一些新疗法，尤其是标靶疗法和免疫疗法，价格高昂，对全球相当一部分患者而言是一个巨大的进入门槛。复杂的监管环境和冗长的新产品审批流程也可能阻碍市场扩张。

非小细胞肺癌治疗市场—关键见解

标靶治疗拥有巨大的市场份额，因为它对治疗特定分子亚型的非小细胞肺癌（NSCLC）非常有效，尤其是最常见的组织学亚型—腺癌。 EGFR、ALK 及其他标靶突变药物的成功研发，使标靶治疗成为 NSCLC 治疗的主流，并提高了大多数存在这些突变的患者无恶化存活期。

预测期内，免疫疗法正经历最快的扩张。这可以归因于其能够在部分患者（即使是晚期患者）中产生持久的疗效和长期生存获益。免疫检查点抑制剂的适应症日益增多，无论是单药治疗还是与化疗或标靶治疗联合治疗，均适用于各种亚型和分期的非小细胞肺癌 (NSCLC)，这推动了免疫疗法的扩张。

预计线上药局将成为成长最快的配销通路。线上管道日益便利、可近性更高，有时更具成本效益，这推动了这一成长。远距医疗和远距照护服务的普及也促进了线上药局在口服非小细胞肺癌药物分销方面的成长。

腺癌占据了最大的市场份额，因为它是全球最常见的非小细胞肺癌组织学亚型，并且通常伴随着某些基因突变，而这些突变可以透过现有的疗法进行标靶治疗。腺癌较高的发生率和可用的标靶疗法使其成为治疗市场的领导者。

非小细胞肺癌治疗市场-細項分析：

全球非小细胞肺癌治疗市场根据治疗、配销通路、癌症类型和地区进行细分。

依疗法类型划分，市场可分为标靶治疗、免疫疗法和化疗。标靶治疗占据了最大的市场份额。其主导地位源自于人们对非小细胞肺癌（NSCLC）分子背景的认识显着提高，而辨识EGFR、ALK、ROS1和BRAF等致癌驱动基因已成为可能。针对这些突变的成功药物的创新和获批，改变了携带此类突变患者的治疗模式，尤其是在腺癌患者中。标靶药物在这些特定患者族群中通常比传统化疗疗效更佳、毒性更小，因此成为初始治疗和后续治疗方案的关键要素。免疫治疗是市场成长最快的领域。这种快速增长得益于免疫检查点抑制剂的颠覆性效应，该抑制剂已被证明能够在一定比例的多种NSCLC亚型患者中产生持续缓解和长期存活。将免疫疗法的适应症拓展至疾病早期阶段，并合併化疗和标靶治疗等其他疗法，正在进一步推动市场成长。

根据配销通路，市场细分为医院药房、零售药房、线上药房和其他。医院药房是最大的细分市场。由于非小细胞肺癌（NSCLC）的治疗类型，该细分市场拥有最大的市场份额，这种治疗通常包括复杂的静脉注射疗法，例如化疗和大多数免疫疗法。医院拥有必要的基础设施，例如专门的输液中心和熟练的医疗保健专业人员，可以安全地提供和监控这些治疗。此外，医院药局通常是住院期间处方药和在专门的癌症中心接受治疗的门诊患者的初始配药点。线上药局是市场上成长最快的领域。电子商务的兴起和线上网站日益便捷的购物体验是其扩张的原因。线上药局让患者能够轻鬆获得用于治疗非小细胞肺癌的口服药物，包括标靶治疗和某些支持性护理药物。它们通常具有竞争力的价格和送货上门的便利性，这对于患有肺癌等持续性疾病的患者尤其有帮助。

非小细胞肺癌治疗市场—地理洞察

北美是非小细胞肺癌药物最大的区域市场。这得益于多种因素，例如完善的医疗基础设施、高昂的医疗支出以及大型製药公司积极推动创新和早期采用新药。美国是肺癌发病率最高的国家之一，但其高效的监管基础设施使其能够快速审批和采用新药。此外，对研发的高度重视以及积极的报销政策也巩固了北美的领先地位。亚太地区是非小细胞肺癌药物成长最快的地区。这种快速增长主要得益于中国和印度等市场庞大且不断增长的患者群体、吸烟和空气污染的日益严重以及医疗保健的可及性和可负担性的不断提高。医疗基础设施支出的不断增长以及免疫疗法和标靶疗法等先进癌症疗法的使用率的不断提高也是主要的成长动力。此外，临床试验数量的不断增加和本地製药行业的蓬勃发展也推动着该地区的快速成长。

非小细胞肺癌治疗市场-竞争格局：

非小细胞肺癌治疗市场竞争激烈，既有实力雄厚的製药和生技公司，也有新进者。基因泰克（罗氏製药）、礼来公司、阿斯特捷利康、辉瑞公司、百时美施贵宝和默沙东等主要公司凭藉其广泛的获批疗法组合、雄厚的研发实力以及完善的全球分销管道，占据了巨大的市场份额。这些公司正在开发新的标靶疗法、免疫疗法和联合疗法，以满足非小细胞肺癌患者不断变化的需求并克服治疗抗药性。策略合作、授权协议和收购也加剧了竞争，旨在扩大产品线和市场覆盖范围。创新是差异化竞争的关键，各公司致力于发现新的治疗标靶、开发下一代抑制剂以及抗体-药物偶联物和细胞疗法等新型治疗方法。人们对个人化医疗和基于生物标记的治疗方法的日益关注也产生了竞争，各公司纷纷投资伴随诊断来确定最有可能对其疗法产生反应的患者亚群。

最新动态：

2024年12月：阿斯特捷利康和第一三共宣布，已向美国食品药物管理局（FDA）提交了一份新的生物製剂许可申请（BLA），以加速批准达托泊单抗德鲁替康（Dato-DXd）用于治疗非小细胞肺癌（NSCLC）。此申请适用于先前接受过治疗的不可切除或转移性非鳞状NSCLC成年患者。

2023年10月：礼来公司宣布FDA核准selpercatinib（Retevmo）用于治疗经FDA核准的检测方法检测出RET融合阳性肿瘤的局部晚期或转移性非小细胞肺癌成年患者。此项批准为该分子亚型的非小细胞肺癌（NSCLC）增加了治疗选择，提供了一种已证实有效的标靶治疗方案。

2023年6月：百时美施贵宝公司宣布，美国食品药物管理局（FDA）批准Opdivo（nivolumab）合併铂类双药化疗作为新辅助治疗，随后进行nivolumab单药辅助治疗，用于可切除（>=4 cm或淋巴结阳性）非小细胞肺癌成年患者。这为更晚期可切除患者在围手术期提供了额外剂量的免疫疗法治疗。

2023年5月：安斯泰来与一家生技公司合作，研发针对多种癌症（包括非小细胞肺癌）的新型抗体药物偶联物。此次合作将结合安斯泰来在抗体工程方面的专业知识与合作伙伴专有的有效载荷技术，以开发更有效、更有针对性的肺癌治疗方法。

目录

第一章：非小细胞肺癌治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 非小细胞肺癌治疗市场（按疗法）
    • 非小细胞肺癌治疗市场依配销通路细分
    • 非小细胞肺癌治疗市场依癌症类型划分
    • 非小细胞肺癌治疗市场（按国家/地区）
    • 非小细胞肺癌治疗市场（按地区）
  • 竞争洞察

第三章：非小细胞肺癌治疗的主要市场趋势

  • 非小细胞肺癌治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 非小细胞肺癌治疗市场限制
    • 市场限制的影响分析
  • 非小细胞肺癌治疗市场机会
  • 非小细胞肺癌治疗市场未来趋势

第四章：非小细胞肺癌治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：非小细胞肺癌治疗市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：非小细胞肺癌治疗市场格局

  • 2024年非小细胞肺癌治疗市占率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：非小细胞肺癌治疗市场－按疗法

  • 概述
    • 按疗法细分的份额分析
    • 标靶治疗
    • 免疫疗法
    • 化疗

第 8 章：非小细胞肺癌治疗市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第九章：非小细胞肺癌治疗市场－依癌症类型

  • 概述
    • 按癌症类型分析细分份额
    • 腺癌
    • 鳞状细胞癌
    • 大细胞癌

第 10 章：非小细胞肺癌治疗市场 - 按地区

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美非小细胞肺癌治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按疗法）
    • 北美市场规模及预测（按配销通路）
    • 北美市场规模及预测（按癌症类型）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲非小细胞肺癌治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按疗法）
    • 欧洲市场规模及预测（按配销通路）
    • 欧洲市场规模及预测（按癌症类型）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区非小细胞肺癌治疗主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依疗法）
    • 亚太地区市场规模及预测（按配销通路）
    • 亚太地区市场规模及预测（依癌症类型）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲非小细胞肺癌治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按疗法）
    • 拉丁美洲市场规模及预测（按配销通路）
    • 拉丁美洲市场规模及预测（按癌症类型）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲非小细胞肺癌治疗主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依疗法）
    • MEA 市场规模及预测（依配销通路）
    • MEA 市场规模及预测（以癌症类型）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 11 章：非小细胞肺癌治疗产业主要供应商分析

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • Eli Lilly and Company
    • Celgene Corporation
    • AstraZeneca
    • Pfizer Inc.
    • Sanofi
    • Novartis AG
    • Astellas
    • Bristol Myers Squibb
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Millennium Pharmaceuticals, Inc. (Takeda)
    • Merck Sharp & Dohme Corp.

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5369

REPORT HIGHLIGHT

Non-Small Cell Lung Cancer Therapeutics Market size was valued at US$ 21,461.20 Million in 2024, expanding at a CAGR of 12.99% from 2025 to 2032.

Non-small cell lung cancer (NSCLC) therapeutics include a wide range of pharmacological and interventional interventions used in the treatment of lung cancers that do not qualify as small cell lung cancer. The therapeutic regimen for NSCLC has come a long way, going beyond the conventional use of chemotherapy to include targeted therapies that take advantage of specific tumour cell genetic mutations and immunotherapies that use the body's immunity against cancer. These therapies suppress cancer cell proliferation, trigger apoptosis (programmed cell death), and suppress metastasis. A therapeutic approach is selected based on factors such as the histological subtype of NSCLC, the stage of cancer at the time of diagnosis, the presence of specific biomarkers, and the patient's health status. The goal of therapy for NSCLC is to prolong survival, improve the quality of life, and palliate symptoms due to disease.

Non-Small Cell Lung Cancer Therapeutics Market- Market Dynamics

The market for non-small cell lung cancer therapeutics is driven by the propelling global incidence of lung cancer due to relentless smoking patterns and rising environmental pollution, which drives the need for efficient treatments. Lung cancer is a major cancer killer globally, according to the World Health Organization. Moreover, the rapid advances in unraveling the molecular underpinnings of NSCLC have opened the way for the rationale of creating targeted therapies and immunotherapies that promise more precise and potentially less toxic treatment. Further investigations into new biomarkers and targets for therapy have the promise to create more personalized medicine modalities. Combining immunotherapy with targeted agents yields encouraging results that enhance patient outcomes, especially in advanced disease.

In addition, the growing use of advanced diagnosis, such as liquid biopsies to identify and track response to early treatment, enables earlier and more effective treatments. The growth in healthcare infrastructure and the rising exposure to sophisticated cancer treatment in emerging markets also offer significant growth opportunities. However, the high price of several new therapies, especially targeted and immunotherapies, is a huge access barrier for a substantial share of the patient population worldwide. The complicated regulatory environment and the long, drawn-out approval process for new products can also hold back market expansion.

Non-Small Cell Lung Cancer Therapeutics Market- Key Insights

Targeted therapy has a substantial market share because it is highly effective in treating specific molecular subtypes of NSCLC, especially adenocarcinoma, the most common histologic subtype. Success with EGFR, ALK, and other actionable mutation-targeted drugs has made targeted therapy a mainstay of NSCLC therapy, resulting in enhanced progression-free survival in most patients with these alterations.

Immunotherapy is witnessing the most rapid expansion during the forecast period. This can be ascribed to its capability to yield durable responses and long-term survival benefits in a proportion of patients, even in advanced disease stages. Growing indications for immune checkpoint inhibitors, both in monotherapy and in combination with chemotherapy or targeted therapy, across various subtypes and stages of NSCLC are fueling this expansion.

Online pharmacies are projected to be the most rapidly growing distribution channel. The growth is fueled by increasing convenience, accessibility, and sometimes cost-effectiveness provided by online channels. Increased adoption of telemedicine and remote care services also enhances the growth of online pharmacies for oral NSCLC medication distribution.

Adenocarcinoma accounted for the largest market share as it is the world's most prevalent histological subtype of NSCLC and often presents with certain genetic mutations that are targetable with therapies presently available. Its larger prevalence and available targeted therapies have helped it become a leading player in the therapeutics market.

Non-Small Cell Lung Cancer Therapeutics Market- Segmentation Analysis:

The Global Non-Small Cell Lung Cancer Therapeutics Market is segmented on the basis of Therapy, Distribution Channel, Cancer Type, and Region.

By therapy, the market is segmented into targeted therapy, immunotherapy, and chemotherapy. Targeted therapy is the most significant share of the market. The dominance results from the vast improvement in realizing the molecular background of NSCLC, where identifying certain oncogenic drivers like EGFR, ALK, ROS1, and BRAF has become possible. The innovation and approval of successful drugs targeting these mutations have transformed the treatment model of patients carrying such changes, especially in adenocarcinoma. Targeted agents commonly demonstrate greater efficacy and better toxicity profiles than conventional chemotherapy in these particular patient groups and, hence, are a key element of initial and follow-up treatment protocols. Immunotherapy is the quickest-growing segment of the market. This fast growth is driven by the game-changing effect of immune checkpoint inhibitors, which have proven the capability to yield sustained responses and long-term survival in a proportion of patients with a range of NSCLC subtypes. Broadening immunotherapy indications to the earlier stages of the disease and combined with other modalities, such as chemotherapy and targeted therapy is further propelling market growth.

Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies are the biggest segment of the market. This segment has the greatest market share because of the type of treatment for NSCLC, which frequently includes the delivery of complicated intravenous therapy like chemotherapy and most immunotherapies. Hospitals have the required infrastructure, such as specialized infusion centers and skilled healthcare professionals, to deliver and monitor these treatments safely. In addition, hospital pharmacies are most often the initial dispensing point for drugs prescribed during an inpatient stay and for outpatients treated in specialized cancer centers. Online pharmacies are the most rapidly expanding sector in the market. The rise in take-up of e-commerce and the growing convenience provided by online websites are the reasons behind this expansion. Online drugstores give patients convenient access to oral drugs employed in treating NSCLC, including targeted treatments and certain supportive care medicines. They tend to have competitive prices and home delivery convenience, which can prove especially helpful for patients with ongoing conditions like lung cancer.

Non-Small Cell Lung Cancer Therapeutics Market- Geographical Insights

North America is the largest regional market for non-small cell lung cancer medicines. This is due to several factors, such as well-established healthcare infrastructure, high healthcare spending, and major pharmaceutical firms pushing innovation and early adoption of new medicines. The US has one of the highest rates of lung cancer and an effective regulatory infrastructure that allows for quick approval & adoption of new drugs. Furthermore, the strong focus on research and development, as well as positive reimbursement policies, adds to the leadership of North America. The Asia-Pacific region has the fastest growth for non-small cell lung cancer drugs. This rapid growth is largely the result of the huge and increasing patient base in markets such as China and India, the growing incidence of smoking and air pollution, and enhancing accessibility and affordability of healthcare. The ever-increasing rate of expenditure on healthcare infrastructure and the increasing rate of utilization of advanced cancer therapies such as immunotherapy & targeted therapy are also major growth drivers. Further, the rising number of clinical trials & development of local pharma industries are pushing the region's rapid growth.

Non-Small Cell Lung Cancer Therapeutics Market- Competitive Landscape:

The market for non-small cell lung cancer therapeutics is a highly competitive one with many entrenched pharma and biotech firms, as well as new entrants. Major players like Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, AstraZeneca, Pfizer Inc., Bristol Myers Squibb, and Merck Sharp & Dohme Corp. command large market shares fueled by the broad portfolios of approved treatments, research and development strengths, and established global distribution channels. These companies are developing new targeted therapies, immunotherapies, and combination regimens to address the evolving needs of NSCLC patients and overcome resistance to treatments. Strategic collaborations, licensing agreements, and buyouts also increased the competitive intensity to expand product pipelines and market coverage. Innovation is an area of differentiator, where firms are targeting the identification of new targets of therapy, next-generation inhibitors, and novel treatment approaches such as antibody-drug conjugates and cell therapies. The rising focus on personalized medicine and biomarker-based treatment approaches also generates competition, with firms investing in companion diagnostics to determine patient subsets most likely to respond to their therapies.

Recent Developments:

December 2024: AstraZeneca and Daiichi Sankyo reported that they had submitted a new biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of datopotamab deruxtecan (Dato-DXd) as a therapy for non-small cell lung cancer (NSCLC). The application is in adult patients previously treated with unresectable or metastatic NSCLC non-squamous.

October 2023: Eli Lilly and Company announced FDA approval of selpercatinib (Retevmo) in adult patients with a rearranged during transfection4 (RET) fusion-positive tumor detected by an FDA-approved test in locally advanced or metastatic non-small cell lung cancer. This approval adds to the treatment options for this molecular subtype of NSCLC, providing a targeted therapy with proven effectiveness.

June 2023: Bristol Myers Squibb reported on the FDA approval of Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as neoadjuvant therapy followed by adjuvant monotherapy for nivolumab alone in adult patients with resectable (>=4 cm or node-positive) non-small cell lung cancer. This allows an additional dose of immunotherapy-based therapy in the perioperative setting for patients with more advanced resectable disease.

May 2023: Astellas collaborated with a biotech firm to discover and develop new antibody-drug conjugates targeting multiple cancers, including NSCLC. The collaboration will combine Astellas' expertise in antibody engineering with the partner's proprietary payload technology to develop more effective and targeted treatments for lung cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Astellas
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc. (Takeda)
  • Merck Sharp & Dohme Corp.

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY - MARKET ANALYSIS, 2019 - 2032

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL - MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE - MARKET ANALYSIS, 2019 - 2032

  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Non-Small Cell Lung Cancer Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Therapy
    • 2.1.2. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Distribution Channel
    • 2.1.3. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Cancer Type
    • 2.1.4. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Country
    • 2.1.5. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Non-Small Cell Lung Cancer Therapeutics Key Market Trends

  • 3.1. Non-Small Cell Lung Cancer Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Non-Small Cell Lung Cancer Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Non-Small Cell Lung Cancer Therapeutics Market Opportunities
  • 3.4. Non-Small Cell Lung Cancer Therapeutics Market Future Trends

4. Non-Small Cell Lung Cancer Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Non-Small Cell Lung Cancer Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Non-Small Cell Lung Cancer Therapeutics Market Landscape

  • 6.1. Non-Small Cell Lung Cancer Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Non-Small Cell Lung Cancer Therapeutics Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2024 & 2032 (%)
    • 7.1.2. Targeted Therapy
    • 7.1.3. Immunotherapy
    • 7.1.4. Chemotherapy

8. Non-Small Cell Lung Cancer Therapeutics Market - By Distribution Channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 8.1.2. Hospital Pharmacies
    • 8.1.3. Retail Pharmacies
    • 8.1.4. Online Pharmacies

9. Non-Small Cell Lung Cancer Therapeutics Market - By Cancer Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Cancer Type, 2024 & 2032 (%)
    • 9.1.2. Adenocarcinoma
    • 9.1.3. Squamous Cell Carcinoma
    • 9.1.4. Large Cell Carcinoma

10. Non-Small Cell Lung Cancer Therapeutics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Non-Small Cell Lung Cancer Therapeutics Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • 11.2.2. Eli Lilly and Company
    • 11.2.3. Celgene Corporation
    • 11.2.4. AstraZeneca
    • 11.2.5. Pfizer Inc.
    • 11.2.6. Sanofi
    • 11.2.7. Novartis AG
    • 11.2.8. Astellas
    • 11.2.9. Bristol Myers Squibb
    • 11.2.10. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 11.2.11. Millennium Pharmaceuticals, Inc. (Takeda)
    • 11.2.12. Merck Sharp & Dohme Corp.

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us